CHAPEL HILL, N.C., Nov. 4 /PRNewswire/ -- As biopharmaceutical companies focus on line extensions and new product development opportunities, fixed-dose combination (FDC) products have become an increasingly important segment of the market. In an effort to better understand the development strategies and issues for new FDC products, a recent study was conducted by Best Practices, LLC, with insights available in the newly published report, "Product Commercialization Excellence: Preparation and Management of Fixed-dose Combination (FDC) Drug Products." The research explored a number of critical questions, including: whether organizations seek additive or synergistic FDC drugs; why companies chose either a bioequivalence or clinical evaluation approach; and whether organizations are using external consultants and for what purposes.
Among the many benchmarks included in this study are timeframes for both bioequivalence and clinical evaluation development approaches and the number, types and frequency of tests required. Executives who are responsible for fixed-dose combination (FDC) drug development can use this data to assess the effectiveness and efficiency of their FDC drug product development programs.
To view the study abstract or complimentary summary of the full report "Product Commercialization Excellence: Preparation and Management of Fixed-dose Combination (FDC) Drug Products," click on the following link http://www3.best-in-class.com/rr973.htm .
In a benchmarking study that included such influential companies as
Abbott, Bayer, Roche, Merck, Pfizer, and Sanofi-Aventis, many key topics
were covered, including:
-- Bioequivalence Approach
-- Clinical Evaluation Approach
-- Lessons Learned
-- FTEs and Complexity
Among the key metrics gathered in this report are:
-- Past, Present and Future Number of FDC Drugs in Development
-- Additive vs. Synergistic Effects
-- Bioequivalence vs. Clinical Evaluation (Preferences and reasons why)
-- Starting Development Prior vs. Post Patent Expiration
-- Use of External Consultants
-- Bioequivalence - Timeframe from Conception to Final Formulation Launch
-- Clinical Evaluation - Timeframe from Conception to Final Formulation
-- Bioequivalence - Timeframe from Initiating Formulation Development to
Final Formulation Launch
-- Clinical Evaluation - Timeframe from Initiating Formulation Development
to Final Formulation Launch
-- Bioequivalence - Multiple Metrics
-- Clinical Evaluation - Multiple Metrics
-- Number of Drugs, FTEs and Timeframe to Reach First/Second Pilot PK
-- Number of Drugs, FTEs and Timeframe to Reach Pivotal BE Study
-- Number of FTEs in Analytical Development
-- Timeframe from Initiating Development Work to CTM Manufacturing for
Class 1/2/4 drugs
For more information on this report, contact Robert Naylor at firstname.lastname@example.org or (919) 767-9244. To access the full report or download a complimentary copy of the report summary, go to http://www3.best-in-class.com/rr973.htm .
ABOUT BEST PRACTICES, LLC
Best Practices, LLC, conducts work based on the simple yet profound principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class companies. For more than 15 years, our highly credentialed research staff has conducted primary research exclusively for our Fortune 500 client base.
|SOURCE Best Practices, LLC|
Copyright©2008 PR Newswire.
All rights reserved